Bicara Therapeutics BCAX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — R&D?
- Bicara Therapeutics (BCAX) reported business segments — R&D of $47.5M in Q1 2026.
- How has Bicara Therapeutics's business segments — R&D changed year-over-year?
- Bicara Therapeutics's business segments — R&D increased by 38.4% year-over-year, from $34.33M to $47.5M.
- What is the long-term trend for Bicara Therapeutics's business segments — R&D?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — R&D has grown at a 102.1% compound annual growth rate (CAGR), from $30.62M to $125.1M.
- What does business segments — R&D mean?
- The aggregate expenditure dedicated to the discovery, development, and clinical testing of new pharmaceutical products. This is a primary indicator of a company's commitment to innovation and its long-term growth potential through pipeline advancement.